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Abstract Depression is a severe neuropsychiatric disor-
der affecting approximately 10% of the world population.
Despite this, the molecular mechanisms underlying the
disorder are still not understood. Novel technologies such
as proteomic-based platforms are beginning to offer new
insights into this devastating illness, beyond those provided
by the standard targeted methodologies. Here, we will
show the potential of proteome analyses as a tool to elu-
cidate the pathophysiological mechanisms of depression as
well as the discovery of potential diagnostic, therapeutic
and disease course biomarkers.
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Depression
Depression, unipolar depression, clinical depression or
major depressive disorder (MDD) is a brain disorder which
affects around 10% of world population [76]. It is char-
acterized by low mood, low self-esteem, inappropriate
guilt, thoughts of death and suicide, diminished
concentration, loss of interest or pleasure in normally
enjoyable activities, and disturbance of sleep and appetite.
In the United States, approximately 3% of depressed
patients commit suicide and around 60% of people who
commit suicide have MDD or another mood disorder
(NIH). MDD is a leading cause of global disability and a
risk factor for non-compliance with medical treatment [11].
MDD appears to be a multifactorial disease arising from
genetic or metabolic predisposition in conjunction with
environmental factors such as stressful life events and other
stressors. Even though there is no anatomical hallmark, the
risk of MDD may be due to signiﬁcant variations in
responsivenessofneuralcircuitsandcanbeaffectedbyother
factors such as addiction or alterations in the dopaminergic
system and the molecular mechanisms of memory [5].
Neuropathological studies have shown volume deﬁcits,
decreased neuronal size and glial pathology as well as
decreased expression of synaptic markers, particularly in
the anterior cingulate, orbitofrontal and dorsolateral pre-
frontal cortices [26]. Hippocampal volume reductions have
been demonstrated by magnetic resonance imaging (MRI)
[53] and may be linked to the effects of stress, hypercort-
isolaemia and hypothalamic–pituitary–adrenal (HPA) axis
dysfunction, although evidence of cellular correlates for
such effects is lacking [26]. Hippocampal neurogenesis has
also been proposed as an underlying factor in the biology
of MDD, mainly based on animal model studies and the
effects of antidepressant medication [13]. For the last three
decades, the main line of investigation into the neurobiol-
ogy of MDD has been focused on changes in the mono-
amine neurotransmitters serotonin and norepinephrine,
based on the known mechanisms of action of drugs with
antidepressant activity. However, the relationship between
low neurotransmitter levels and symptomatology is not
simple and may be dependent on genetic background [1].
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response time is lengthy in many cases with a high rate of
relapse and treatment resistance [62], novel lines of
research are warranted.
Numerous studies have used molecular proﬁling tech-
nologies to examine the brains of MDD patients with or
without suicidality. Several groups have used microarray
approaches to demonstrate abnormalities in the expression
of transcripts related to synaptic transmission, particularly
glutamate and GABAergic signalling, in the brains of
depressed patients with or without suicide, especially in
frontal and limbic regions [8, 34, 64, 65], with one negative
study [68]. Subtle differences between suicides with MDD
and non-MDD suicides have been detected leading some
authors to postulate that there may be underlying differ-
ences in stress response [34]. Another study found two
genes differentially expressed between suicide and non-
suicide patients across schizophrenia (SCZ) and bipolar
disorder (BPD) subjects [33]. Further studies have used
proﬁling methods to investigate the role of cholesterol in
MDD, as altered blood cholesterol levels have been
reported in MDD subjects, presenting a potential link with
synaptic abnormalities in the brain. Lalovic et al. [38]
proﬁled fatty acids in two regions of the frontal cortex and
found no differences between suicide completers (with or
without MDD) and controls, but found a decrease in cho-
lesterol content in the frontal cortex of violent suicides only
[39]. Further studies by the same group found differential
expression of lipid metabolism and immune response genes
using microarray analyses in frontal cortex of depressed
suicide completers [40].
These signiﬁcant and convergent ﬁndings are promising,
and transcriptomics can provide information about a wide
range of gene products and lead to the generation of new
hypotheses. However, further investigation of the protein
products of relevant genes is required in order to demon-
strate a functional abnormality. In this respect, proteomics
provides a useful complimentary approach and takes the
understanding of brain function closer to a functional and,
therefore, disease-determining endpoint. In recent years,
proteomics has been used as a tool for better comprehen-
sion of human brain disorders as well as for the discovery
of biomarkers for diagnosis, or for monitoring disease
course, treatment response and the identiﬁcation of novel
therapeutic targets.
Proteomics
Deﬁnition
The term proteomics was originally deﬁned as ‘‘the study
of the total set of expressed proteins by a cell, tissue or
organism at a given time under a determined condition’’
[75]. The proteome also includes the modiﬁcations made to
a particular set of proteins produced by an organism or
cellular system and this can vary with time and distinct
requirements, stresses, or other environmental factors that a
cell or organism is subjected to. Proteomic technologies
allow the study of a subset of these proteins and differen-
tially expressed proteins can usually be identiﬁed in com-
parisons of two or more different states.
Methods for proteome characterization
2D-PAGE
Most proteomic analyses are performed using a combina-
tion of two-dimensional gel electrophoresis (2DE) for
protein separation and mass spectrometry (MS) for protein
identiﬁcation. This combination of technologies allows the
simultaneous separation of many hundreds of proteins in a
single experiment. Direct comparison of 2DE proﬁles from
different samples combined with unambiguous identiﬁca-
tion of the separated proteins by MS is the typical format
followed by most researchers.
2DE has been extensively and successfully used in
studies of brain tissue or body ﬂuids of psychiatric disor-
ders such as SCZ [46, 49, 60] and BPD [2, 17] as well as in
studies of neurodegenerative disorders such as Alzheimer’s
disease (AD) [25, 72, 74]. These studies have identiﬁed a
number of proteins that could be involved in disease
pathogenesis, increasing the understanding of such disor-
ders. Despite the separation power of this approach, 2DE–
MS-based proteomics presents some limitations such as a
difﬁculty in detecting low-abundance, acidic or basic pro-
teins as well as proteins with extremes of high or low
molecular weight [24]. This has led researchers to ﬁnd
alternative ways to study the proteome.
Shotgun proteomics
An alternative direct MS-based approach has been devel-
oped to avoid such drawbacks [44]. This is generally
known as shotgun proteomics or liquid chromatography–
tandem mass spectrometry (LC–MS/MS) which uses a
combination of chromatographic steps prior to MS analyses
in a high-throughput way. Protein quantitation of shotgun
approaches, especially when stable-isotope methods are
used, is more accurate than the 2DE–MS approach. One
potential drawback of shotgun approaches is that they are
not capable of providing direct information on intact pro-
teins, as is the case for 2DE. However, shotgun proteomics
has been used in SCZ studies, revealing some differentially
expressed proteins that have not be found by 2DE methods
[47, 48].
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While 2DE and shotgun approaches are used to reveal the
global protein expression of a given tissue, other methods
such as Western blot (WB), enzyme-linked immunoad-
sorbent assay (ELISA), multiple reaction monitoring
(MRM) mass spectrometry and antibody arrays are
employed commonly for validation of differentially
expressed proteins. Validation is necessary to demonstrate
that the differences found in a limited small set of samples
can also be found in a broader universe of samples, con-
sidering factors such as age, gender and different ethnici-
ties. Moreover, there is a necessity to implement and
improve high-throughput methods for validation studies
such that high sample numbers are not a limiting factor.
Luminex bead-based approach
The recent introduction of ﬂuorescent bead-based tech-
nologies allows the simultaneous measurement of multiple
analytes in individual small-volume samples, revolution-
izing proteomic analyses. This analytical platform is also
suitable for further development of convenient, rapid,
sensitive and speciﬁc diagnostic assays. This technology
employs multiplexed dye-coded microspheres, coated with
speciﬁc capture reagents for assaying targeted analytes
within clinical samples. Identiﬁcation and quantitation of
the analytes are achieved by laser excitement within an
analyser. The format allows multiplexing of up to 100
distinct assays for a single sample. This approach mini-
mizes sampling errors, the amount of sample required for
each analysis and the requirements and costs of assay
reagents. Such technology, still not well implemented in
studies of brain disorders, has already been applied suc-
cessfully in numerous clinical studies or biomarker dis-
covery projects of diseases such as epithelial ovarian
cancer [6], scleroderma [15], coronary artery disease [23],
myocardial infarction [18], autoimmune disorders [10] and
sickle cell anaemia [42].
Metabolomics
Comparative proteome analyses of human brain tissue have
led to the identiﬁcation of biochemical pathways and
consequently have provided some indication of the asso-
ciated metabolites. The quantitation of metabolites using
diverse approaches can provide a more complete picture of
brain activities which may be useful for comprehension of
the biochemical processes as well as a means of providing
a source of non-protein-based biomarkers.
Targeted analysis of metabolites has been used to func-
tionallyvalidateproteinexpressionchanges.Sincewefound
that key glycolysis enzymes were differentially expressed in
SCZ thalamus, we measured the levels of pyruvate and
NADPH using a simple enzymatic assay and conﬁrmed that
these metabolites were also differentially expressed [51].
The advent of high-resolution proton nuclear magnetic
resonance spectroscopy (
1H-NMR) has provided a means of
multiplexing analyses of metabolites providing greater
accuracy and higher throughput.
1H-NMR metabolomics
has been used to observe the effects of a number of psy-
chotropic drugs on rat brain metabolites and signiﬁcant
differences were found regarding N-acetylaspartate (NAA)
levels [54]. Moreover, high-performance liquid chroma-
tography (HPLC) has been used to quantify signiﬁcant dif-
ferences in the polyamines putrescine and spermidine in
high anxiety-related behaviour (HAB) and low anxiety-
related behaviour (LAB) brain tissue extracts [12].
Since all of the molecular proﬁling methods described
here have their strengths and weaknesses, the combined use
of two or more of these would be best to maximize cov-
erage of the relevant molecular pathways such as those
described by Salim et al. [63] in the characterization of
proteome differences that occur during the differentiation
of neural precursor cells or as applied in the proteome
analysis of SCZ thalamus compared to healthy controls by
Martins-de-Souza et al. [51].
Proteomics in psychiatric disorders
Despite considerable efforts, there is still a lack of animal
models for psychiatric disorders, with only a few that are
well-established. For SCZ, e.g., it is difﬁcult to model
symptoms in animals that reﬂect the human condition. This
is one of the main driving reasons why researchers have
focused mainly on the analysis of human postmortem brain
tissues and ﬂuids from SCZ and BPD patients. The main
goal of these human studies is a better comprehension of
the pathophysiology of such disorders as well as identiﬁ-
cation of biomarker candidates and potential novel targets.
Indeed, such proteome analyses have successfully identi-
ﬁed components of molecular pathways involved in psy-
chiatric disorders, thereby demonstrating the potential of
these methods in this ﬁeld of research.
Schizophrenia
Nine different brain regions from SCZ patients have been
subjected to proteomic analyses using different methodol-
ogies [2, 3, 9, 17, 31, 46–49, 51, 59, 60, 69]. In addition,
serum and cerebrospinal ﬂuid (CSF) from SCZ patients
have been analysed [30, 43, 51, 61]. The most frequent
protein alterations identiﬁed were related to energy, oli-
godendrocyte and phospholipid metabolism as well as
Ca
2? homeostasis [52].
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ated with reactive oxygen species has been observed [77]
as well as alterations in mitochondrial oxidative phos-
phorylation [27, 73] and glucose metabolism [4]. Proteome
analyses have identiﬁed differential expression of proteins
involved in those processes, such as key enzymes associ-
ated with glucose metabolism including aldolase C (AL-
DOC), gamma enolase (ENO2), aconitase (ACO2),
hexokinase (HK1), glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), a number of subunits of mitochondrial
ATPase and proteins associated to oxidative stress [52].
Oligodendrocytes are responsible for myelination of
axons in the central nervous system (CNS). Reduction or
malformation of the myelin sheath can result in leakage
and reduced propagation of nerve impulses [14]. Dys-
function of oligodendrocytes has been demonstrated for
SCZ using imaging techniques such as diffusion tensor
imaging (DTI) and magnetization transfer imaging (MTI)
[20, 36]. In addition, proteome analyses have conﬁrmed
this through identiﬁcation of differentially expressed pro-
teins such as Myelin basic protein (MBP), myelin oligo-
dendrocyte glycoprotein (MOG) and 20,30-cyclic
nucleotide,30-phosphodiesterase (CNP) [52].
Potential biomarkers such as apolipoprotein A1
(APOA1) have been identiﬁed in CSF, red blood cells and
serum from ﬁrst-onset drug-naive SCZ patients [30, 43,
61]. In addition, apolipoprotein A2 and A4, and transferrin
have been identiﬁed as differentially expressed in serum of
SCZ subjects [43].
Bipolar disorder
Proteome analyses of BPD human brain tissue have also
been performed. Dihydropyrimidinase-related protein-2
(DPYSL2) and glial ﬁbrillary acid protein (GFAP) were
found to be decreased in the frontal cortex (FC-BA10)
suggestive of effects on brain development. The differen-
tial expression of several tubulin subunits suggested that
cytoskeletal dysfunction may be an important component
of BPD through an analysis of the anterior cingulate cortex
(ACC-BA24) [2].
One common ﬁnding in proteomic studies of distinct
brain regions from BPD patients is suggestive of a dys-
function in energy metabolism [2, 31, 58], more promi-
nently in the dorsolateral prefrontal cortex (DLPFC-BA9)
where half of the identiﬁed differentially expressed pro-
teins were involved in these pathways [59].
Animal models
The study of animal models of psychiatric disorders has
advantages over analyses of the corresponding human tis-
sue, since laboratory animals show greater genetic
homogeneity and are not fraught with confounding factors
such as alcohol and tobacco consumption. However, the
direct study of human samples has a key advantage over
animal models in that the generated data are related to the
disease itself, and in many cases the validity of psychiatric
animal models has not been fully determined.
Proteomics in depression research
Proteome of human samples
At present, only two brain regions, the frontal cortex (FC)
and accumbens (ACC), from depressed patients have been
subjected to proteomic analyses, revealing differentially
expressed proteins [2, 31]. Altered expression of DPYSL2
was common to both studies, although this was downreg-
ulated in FC and upregulated in ACC. DPYSL2 plays a role
in nervous system development and cell differentiation by
regulating axonal guidance, neuronal growth cone collapse
and cell migration, suggestive of alterations in brain
development in depressed patients. The differential
expression of carbonic anhydrase (CA2) and ALDOC was
also common to both studies, implicating effects on energy
metabolism.
Both of these studies used brain tissue samples from the
Stanley Neuropathology Consortium and analysed samples
from MDD, SCZ, BPD and control subjects simulta-
neously. In addition, studies using CSF from depressed
patients have been carried out, but only in a validation
context for SCZ ﬁndings [29]. Thus far, no systematic
proteomic study has been carried out on brain tissues from
depressed patients. Considering the importance of this
disorder and the effects on society, more studies in human
tissue and ﬂuids from such patients are required.
Proteome studies of depression using animal models
The difﬁculty in comprehending the complex regulation of
gene and protein expression and interactions with envi-
ronmental and external factors such as drug treatment is the
main reason that researchers have focused their efforts on
investigating samples from animal models rather than those
from the human disease condition.
Most of the proteomics studies relating to MDD have
focused on the response to drug treatments. Nowadays,
MDD treatment is widely based on the prescription of
biogenic-amine-based agents that selectively block the
uptake of serotonin and/or norepinephrine. Such treatments
differ from previous long-standing treatments, based on the
increase of serotonin and norepinephrine levels in syn-
apses, even though the therapeutic drawbacks still remain
which are most likely intrinsic to treatment mechanism
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pocampal volume in depressed patients [66] might be
affected by antidepressants which reverse the shrinkage of
hippocampal neurons, improving the symptoms of the
disease [16]. Some articles have also demonstrated that
antidepressant treatment may modulate molecules associ-
ated with neurogenesis [45] such as brain-derived neuro-
trophic factor (BDNF) [57]. This has been demonstrated in
brain tissue from knockout mice for neurokinin-1 (NK1)
receptor gene, since antagonists for this receptor show
antidepressant activity [55]. Interestingly, BDNF can
induce antidepressant effects [67] probably because this
molecule can increase neurogenesis in hippocampus [41]
as well as 5HT and noradrenaline [21, 37]. Despite all the
knowledge regarding treatment, the mechanisms of anti-
depressant drugs still require further elucidation. Proteome
analysis could be helpful for the better understanding of
antidepressant treatments, especially because proteome
analyses can reveal the proteins involved in such mecha-
nisms as well as the identiﬁcation of potential biomarkers
[50].
Impairments in the HPA axis have led most proteomic
researchers to investigate the hypothalamus in these mod-
els. The known imbalances in monoamine levels in brains
from depressed patients have driven comparative proteo-
mic studies on the mechanism of action of monoamine
reuptake inhibitors such as venlafaxine, a serotonin–nor-
epinephrine reuptake inhibitor (SNRI), or ﬂuoxetine, a
selective serotonin reuptake inhibitor (SSRI). Adult rats
treated for 2 weeks with such drugs have shown the dif-
ferential expression of more than 30 proteins that play roles
in neurogenesis, maintenance of neuronal processes and
regeneration [32]. Studies of mice treated with chronic
corticosterone have been carried out in hypothalamus,
hippocampus and cerebral cortex, resulting in identiﬁcation
of alterations in energy pathway enzymes and phenylala-
nine, glutamate and nitrogen metabolism. Moreover,
pathway analysis suggested an alteration in cell morphol-
ogy in the hippocampus and cerebral cortex, and cell death/
survival pathways in the hypothalamus of these mice [71].
Other proteomic studies have used a mixture of neural and
glial cells in culture after exposure to 1 mM of paroxetine
for 14 days in order to understand antidepressant action.
The observed upregulation of sepiapterin reductase (SPR)
was interesting as this enzyme is involved in modulating
the synthesis of neurotransmitters such as serotonin.
Moreover, the upregulation of heat shock protein 9A and
protein disulﬁde isomerase as well as the downregulation
of creatine kinase, prohibitin, glial ﬁbrillary acidic protein
and vimentin suggests that these may be involved in the
mechanism of action of antidepressant medication and may
also offer some insight regarding the pathogenesis of
MDD.
The effects of ﬂuoxetine in guinea pigs showed altera-
tions in the proteome regarding neuroﬁlaments, suggestive
of effects on synaptic remodelling. Validation studies using
immunohistochemistry and electron microscopy were car-
ried out showing an increase in post-synaptic neurons with
split post-synaptic densities, which may explain why
antidepressants take weeks to months before their thera-
peutic effects are realized [22].
Proteomic studies of hippocampus from a chronic stress
rat model of MDD identiﬁed 27 differentially expressed
proteins with a role in neurogenesis and oxidative metab-
olism [56]. Another study reported on analysis of the hip-
pocampal proteome of different treatment groups using the
chronic mild stress model of MDD in rats with the aim of
identifying potential biomarkers for anhedonia, escitalop-
ram resistance and stress resilience. Thirteen proteins were
identiﬁed as differentially expressed between the groups
and interestingly, DPYSL2 was identiﬁed as a biomarker
for escitalopram resistance. Moreover, the authors claimed
that cellular plasticity is an important issue for the under-
standing of the molecular mechanism of MDD [7].
Extensive proteomic studies have been conducted
regarding the HAB and LAB mice model. HAB mice are
hyperanxious representing a comorbid depression-like
behaviour according to elevated plus-maze (EPM), tail
suspension (TST) and forced swim tests (FST) [28]. Pro-
teome analyses of HAB/LAB mice led to the identiﬁcation
of glyoxalase-I as a protein marker downregulated in
multiple brain areas [35] and an alternate enolase phos-
phatase isoform in HAB mice [12].
Limitations
Despite the contribution of studies of animal models,
investigation of the human brain is essential to further
understand the causes and symptomatology of MDD, and
particularly in the investigation of suicidality. Nonetheless,
careful consideration of experimental design and potential
confounders must be taken. This is as much a problem for
proteomic investigations as with other areas of research. As
with all psychiatric disorders, some awareness of the role
of lifestyle factors is important. Chronically ill patients
may have different diets, access to healthcare and exercise
levels compared to control subjects. Given the known
effects of exercise on hippocampal function, records of
exercise levels, body mass indices (BMIs) and measure-
ments of metabolic parameters may be necessary in the
interpretation of postmortem ﬁndings. Furthermore, as
medication is generally the ﬁrst-line approach for treatment
of MDD, the majority of study subjects will have been
medicated at some stage of the illness. This can only be
addressed by collecting samples from subjects at ﬁrst
presentation for peripheral studies, and in postmortem
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with the known effects of antidepressant medication.
Alcohol and substance misuse are common problems
amongst MDD patients and represent important confounds
as the neurobiological effects of these drugs may overlap
with those found in non-abusing MDD patients. Indeed,
whether MDD arises as cause or effect of substance misuse
merits contemplation. Similarly, there is a high degree of
co-morbidity with MDD, suicide and other disorders such
as AD, BD and SCZ. Moreover, the study of mood disor-
ders requires consideration of the state versus trait problem,
namely whether the detected changes are simply correlates
of mood or a reﬂection of the underlying biology which
predisposes the subject to such abnormal mood states.
Attempts to assess and control for these factors can be
made by studying a range of patient types and subtypes
postmortem, and by comparison with data from living
patients and preclinical models. Bioinformatic strategies
can also be used to distinguish signal from noise and
incorporate relevant variables in the data analysis pipeline.
Proteomics presents an ideal route to address these factors
as the methods are applicable across species and in all
tissues and ﬂuids of the human body. However, some
confounds will inevitably remain and this must be taken
into account when considering the data.
Conclusions and perspectives
The sequencing of human genome brought in the 1990s a
renewed hope regarding the molecular understanding and
more effective treatments for many diseases such as psy-
chiatric disorders. But the exceedingly large and valuable
amount of data that the human genome project provided
requires considerable further study and data mining to
maximize the impact. Proteomic studies may offer further
insights, helping to unlock the function of the genome.
Proteome generated data can be interpreted through sys-
tems biology analysis in order to comprehend the causes
and consequences of complex psychiatric disorders such as
MDD. Moreover, identiﬁcation of differentially expressed
proteins using proteomics, principally in body ﬂuids, can
provide biomarkers to facilitate the development of early
diagnostics, more effective treatments and other ends.
Most studies regarding protein expression in MDD have
been carried out in animal models as described above,
since there is a necessity to eliminate environmental and
external factors that can confound the ﬁndings as well as to
observe the effects of treatments. Despite these efforts,
there is considerable scope for understanding more about
this disorder, which could lead to identiﬁcation of diag-
nostic/prognostic biomarkers and potential novel thera-
peutics. For example, it is known that physical exercises
such as running can reverse hippocampal dysfunction in
depressed patients, and this could be mediated by proteins
such as the pituitary nerve growth factor VGF [19]. Pro-
teomic analysis of models involving over- or under-
expression of VGF would help to compose a better over-
view of neurotrophic signalling pathways in MDD. More-
over, despite the importance of studying animal models, it
is also necessary to study human tissues such as post-
mortem brain tissue and peripheral ﬂuids such as blood and
CSF from human patients in order to construct a more
complete scenario of MDD, as has been done in SCZ and
BPD studies. For example, studying body ﬂuids from
depressed patients who have attempted suicide could lead
to identiﬁcation of markers for suicide risk as well as
biomarkers of brain function. These studies could allow a
ranking for risk of suicidal behaviour according to a pro-
teomic ﬁngerprint.
Even with all of the invested efforts to date, the ﬁeld of
proteomics in MDD studies still needs to be explored more
deeply.
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